NEOG · Neogen Corporation

The thesis

Neogen's turnaround now has a plan with numbers attached: a first-quarter beat, a raised fiscal 2027 outlook and, at the 7 October 2026 investor day, a target of about 30% adjusted EBITDA margins by fiscal 2031. The shares have not yet rewarded it. Clearance of the Genomics sale to Zoetis, which Neogen expects by the end of December 2026, settles whether debt falls on the promised schedule.

Neogen reported on 6 October 2026 after the close. Revenue of $222.8 million beat the company's own $207–209 million guide, and fiscal 2027 revenue guidance rose to $885–890 million from $880–885 million. A day later, management set fiscal 2031 targets for high-single-digit to low-double-digit revenue growth, high-50% adjusted gross margins and about 80% free-cash-flow conversion, MarketBeat reported on 7 October 2026.

The market's reaction is the weak part of the case. Investing.com reported the shares up about 8% after hours on 6 October 2026, yet the adjusted close of $11.71 on 8 October 2026 sat below the $11.96 pre-report close. The narrative is maturing: the investor day put the long-term plan on the record, and the shares closed below their pre-report level two sessions later despite the beat and raise.

The view that the recovery is durable is wrong if the shares close below $11.40, or if Neogen cuts the raised revenue guide or regulators block the Genomics sale.

Bullish and bearish views on Neogen Corporation

The bull case on Neogen Corporation (NEOG), in brief: Growth sped up in the weakest quarter. The bear case: The beat did not hold in the price.

Bull case

• Growth sped up in the weakest quarter. Neogen's 6 October 2026 release reported core growth of 8.1%, which excludes currency and divestitures. Food Safety revenue was $163.2 million with 8.1% core growth, against 5.8% Food Safety core growth in the fiscal fourth quarter of 2026.
• Full-year adjusted EBITDA guidance rose to $181–183 million.
• Long-term targets are now public. At the 7 October 2026 investor day, management targeted about 30% adjusted EBITDA margins and research spending near 5% of revenue by fiscal 2031, MarketBeat reported. Strategic-account growth was 6.2% year to date, with a goal above 8% by year-end.
• Operations have improved. Management said complaints fell 65%, inventory 23% and back orders 27% over the past year, according to MarketBeat's 7 October 2026 investor-day summary.
• Debt is coming down. Management said on the 6 October 2026 call that Neogen repaid $20 million in June and $10 million at the end of September. Net leverage is about 3x, and the investor-day target is below 2.5x.
• Analysts see room above the price. Guggenheim raised its target to $14 on 30 September 2026, and Piper Sandler upgraded the shares with a $14 target on 26 August 2026.

Bear case

• The beat did not hold in the price. The adjusted close of $11.71 on 8 October 2026 was below the $11.96 close of 6 October 2026, before the results. A beat-and-raise quarter plus a five-year plan failed to lift the shares above their pre-report level.
• Reported earnings remain negative. Neogen posted a net loss under generally accepted accounting principles of $11.9 million, or 5 cents a share, per the 6 October 2026 release. Adjusted earnings of 8 cents a share leave out transformation and integration costs.
• The Genomics timeline has slipped. The 6 October 2026 release says Australian and New Zealand reviews should end by December 2026, later than the prior plan for completion by 30 November 2026. About $140 million of debt reduction waits on the outcome.
• The HYCOAT case is unresolved. The U.S. Food and Drug Administration (FDA) issued warning letters to Neogen and contract manufacturer Sciarra Aeromed, linking contaminated Neogen Vet HYCOAT to infections in nearly 100 horses, Beef Magazine reported on 29 September 2026. Neogen has not disclosed a related charge.
• The Petrifilm switch is a multi-quarter execution job. Neogen is moving 17 product codes from 3M supply to its own plant, with the 3M agreement running through August 2027, MarketBeat reported on 7 October 2026. Management expects products from the new plant to reach customers early in calendar 2027.
• Short interest is elevated. Short interest rose to more than 11 million shares in the mid-September reporting period, Quiver Quant reported, which can sharpen daily moves in either direction.

Price setup

The adjusted close on 8 October 2026 was $11.71. That is 16.2% below the $13.98 52-week high and 21.3% above the level of three months earlier. The 14-day relative strength index (RSI), a momentum gauge running from 0 to 100, stood at 38.4, toward the weak end of its range.

The shares fell to an adjusted $11.96 on 6 October 2026 from $13.01 on 5 October 2026, below the $12.15 low close that followed the FDA news on 2 October 2026. The after-hours gain on the results then faded. Benzinga reported the shares higher on 8 October 2026 after the investor-day targets, which left the stock still under its pre-report close.

Crowding signs are mixed. Retail attention rose with the FDA headlines and the investor day, and short interest above 11 million shares adds volatility. The price sits well below the 52-week high, so there is no stretched gap above recent trading. The next earnings report is about three months away.

Catalysts, next 30 days

• 27 November 2026 — Australian Competition and Consumer Commission (ACCC) Phase 2 decision date on Zoetis' purchase of the Genomics business, as published in July. Neogen now expects reviews to end by December 2026, so the date may move.
• ~31 December 2026 (est.) — Company-expected end of Australian and New Zealand reviews. Clearance funds the move toward net leverage below 2.5x.
• ~7 January 2027 (est.) — Fiscal second-quarter 2027 report. It shows whether 8.1% core growth carries past the seasonally weak first quarter.

Elapsed catalysts

• November 2026 (est.) — Start of the Petrifilm manufacturing transition at Neogen's new plant, which has more than three times its current Petrifilm capacity, per investor-day remarks reported on 7 October 2026. A delay or supply gap would hit the Food Safety segment that carries the raised guide. (passed 5d ago)

What would change the view

The case breaks if Neogen cuts its $885–890 million fiscal 2027 revenue guide, or if Food Safety core growth falls back below the 5.8% of the fiscal fourth quarter of 2026. A prohibition or forced remedy from the ACCC or New Zealand's Commerce Commission would remove the planned debt reduction. A disclosed HYCOAT charge, lost sales or further FDA action at a Neogen-run site would also break it, as would a delay to the Petrifilm transition.

On price, a daily close below $11.40 would extend the fade below the $11.96 pre-report close and show the market rejecting both the quarter and the five-year plan. A close back above the $11.96 pre-report level would show buyers accepting the results.

What it trades with

Neogen trades mainly on its own turnaround: guidance, the Genomics sale and the Petrifilm plant. Its food-safety testing peers include bioMérieux and 3M's former food-safety unit, which Neogen absorbed in 2022. The Genomics sale ties one event to Zoetis and to Australian competition review. Rate sensitivity runs through debt of about $774 million cited on the 6 October 2026 call. Benzinga's 6 October 2026 market preview put the 10-year Treasury yield at 5.34%, a level that weighs on leveraged small and mid-cap names.